Akero Therapeutics Stock

Akero Therapeutics Market capitalization 2025

Akero Therapeutics Market capitalization

1.35 B USD

Ticker

AKRO

ISIN

US00973Y1082

WKN

A2PLNP

In 2025, Akero Therapeutics's market cap stood at 1.35 B USD, a 20.17% increase from the 1.12 B USD market cap in the previous year.

The Akero Therapeutics Market capitalization history

YEARMarket Capitalization (undefined USD)
20232.05
20220.84
20210.95
20200.84
20190.33
2018-
2017-

Akero Therapeutics Aktienanalyse

What does Akero Therapeutics do?

Akero Therapeutics Inc is an advanced biotherapy company focused on the development and commercialization of medications to improve patient health. The company was founded in 2017 by five experienced pharmaceutical experts: Andrew Cheng, Timothy Lu, David D. Kirn, Scott Freeman, and Stuart Lockhart. Akero Therapeutics Inc is headquartered in Belmont, California, USA. The business model of Akero Therapeutics Inc is based on targeted biological therapy aiming to address unmet medical needs in various disease areas. The idea is to reduce the risk of diseases such as diabetes, chronic liver diseases, and metabolic disorders and improve the quality of life for patients through the development of innovative biological agents. Akero Therapeutics is dedicated to combating these diseases with groundbreaking therapeutic approaches. The company offers various divisions including product development, research and development, and commercial. Product development at Akero Therapeutics encompasses the discovery, development, clinical testing, and efficacy assessment of new biological agents. The research division continuously works on identifying new target molecules to develop innovative approaches in disease therapy. The commercial division of Akero Therapeutics is responsible for developing an appropriate marketing strategy to bring the biological agents to market readiness and to patients. One of the most well-known products of Akero Therapeutics is the medication Efruxifermin (EFX). It is a protein molecule developed for the treatment of patients with non-alcoholic fatty liver disease (NAFLD). NAFLD is a disease characterized by the accumulation of fat in the liver without the patient consuming alcohol during the day. Fatty liver disease is a growing public health issue and one of the most common liver diseases worldwide. Akero Therapeutics has developed an effective medication, EFX, which effectively reduces liver fat content. Another product currently in the clinical research phase at Akero Therapeutics is AKR-001. It is a medication for the treatment of patients with lipid metabolism disorders, including hypertriglyceridemia and homozygous familial hypercholesterolemia. Lipid metabolism disorders are characterized by high levels of triglycerides and cholesterol in the blood and increase a patient's risk for cardiovascular diseases. In summary, Akero Therapeutics is a clinical biotherapy company dedicated to the development of treatments for various chronic diseases. The company combines innovative research with strong entrepreneurial capabilities to explore, develop, and bring new biological agents to the market for disease therapy. Akero Therapeutics is on track to establish a strong presence in the biopharmaceutical industry and has the potential to improve the lives of millions of patients worldwide. Akero Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Market capitalization Details

Exploring Akero Therapeutics's Market Capitalization

Akero Therapeutics's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Akero Therapeutics's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Akero Therapeutics's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Akero Therapeutics’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Akero Therapeutics stock

What is the current Akero Therapeutics market capitalization?

The current market capitalization of Akero Therapeutics is 1.35 B USD.

What is market capitalization?

The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like Akero Therapeutics.

How has the market capitalization of Akero Therapeutics developed in recent years?

The market capitalization of Akero Therapeutics has increased/decreased by 20.17% compared to the previous year.

What does market capitalization mean for investors?

The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.

Why is market capitalization an important indicator for investors?

The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.

Why does the market capitalization fluctuate?

The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.

What role does market capitalization play in the valuation of Akero Therapeutics?

In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.

Does the market capitalization influence the performance of Akero Therapeutics?

There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

Does the market capitalization of Akero Therapeutics have an influence on indices?

Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).

How much dividend does Akero Therapeutics pay?

Over the past 12 months, Akero Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Akero Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Akero Therapeutics?

The current dividend yield of Akero Therapeutics is .

When does Akero Therapeutics pay dividends?

Akero Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Akero Therapeutics?

Akero Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Akero Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Akero Therapeutics located?

Akero Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Akero Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Akero Therapeutics from 1/22/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/22/2025.

When did Akero Therapeutics pay the last dividend?

The last dividend was paid out on 1/22/2025.

What was the dividend of Akero Therapeutics in the year 2024?

In the year 2024, Akero Therapeutics distributed 0 USD as dividends.

In which currency does Akero Therapeutics pay out the dividend?

The dividends of Akero Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Akero Therapeutics

Our stock analysis for Akero Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Akero Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.